It is possible to have a high A1C without an established diabetes diagnosis. An A1C of 5.7% to 6.4% is in the prediabetes range. An A1C of 6.5% or higher meets a diabetes diagnostic threshold, but—unless symptoms and glucose levels make the diagnosis clear—it should be confirmed promptly with a repeat laboratory A1C or another accepted diagnostic test. A normal fasting glucose does not automatically cancel out a diabetes-range A1C.
Sometimes the result and the glucose data genuinely disagree. Recent blood loss, iron deficiency, altered red-cell turnover, kidney failure, pregnancy, transfusion, and certain hemoglobin variants can change how A1C should be interpreted. This guide explains how to distinguish true high glucose from a false high A1C and how clinicians investigate an A1C and glucose mismatch.
The phrase usually describes one of three situations:
For a broader introduction to diagnostic testing, see Diabetes and Prediabetes Blood Tests: A1C, Glucose, Insulin, and C-Peptide.
| Laboratory A1C result | Usual diagnostic category | Important interpretation note |
|---|---|---|
| Below 5.7% | Below the prediabetes threshold | Does not exclude every glucose problem, especially when symptoms, risk, pregnancy, or a condition affecting A1C is present. |
| 5.7% to 6.4% | Prediabetes | Risk increases across the range. Results near a threshold should be interpreted with clinical context and followed over time. |
| 6.5% or higher | Diabetes threshold | In the absence of unequivocal hyperglycemia, confirm with a second abnormal result. Use an NGSP-certified laboratory method for diagnosis. |
These cutoffs apply to nonpregnant adults in the usual diagnostic setting. A1C is not the preferred diagnostic test for gestational diabetes, and it may be unsuitable in several conditions that alter red-cell turnover. Diagnostic cutoffs also are not the same as an individualized treatment target for someone who already has diabetes.
An A1C test reports the percentage of hemoglobin with glucose attached to it. Because red blood cells circulate for about 120 days, A1C reflects an integrated, recently weighted picture of glucose exposure over approximately two to three months. The most recent weeks influence the result more than the earliest weeks in that period.
A1C does not show the timing of glucose peaks and lows. Two people can have the same A1C but very different daily patterns. It also assumes a reasonably typical red-cell lifespan. If red cells live longer or shorter than expected—or if the assay measures a hemoglobin variant differently—the reported A1C may not accurately represent average glucose.
A fasting glucose test is a snapshot after an overnight fast. A1C is a longer-term, weighted average. They answer related but different questions, so a modest difference is not automatically an error.
| Pattern | What may explain it | What often clarifies it |
|---|---|---|
| High A1C, normal fasting glucose | Post-meal glucose elevations; day-to-day variation; iron or vitamin deficiency; altered red-cell lifespan; assay interference | Repeat laboratory A1C, fasting plasma glucose, or a 75-gram two-hour oral glucose tolerance test, selected for the clinical question |
| Normal A1C, high glucose | Recent-onset hyperglycemia; acute illness; steroid exposure; blood loss or hemolysis; pregnancy; kidney failure; a hemoglobin variant | Prompt repeat or confirmation with an accepted plasma-glucose test; investigate symptoms and red-cell context |
| A1C does not match home meter or CGM patterns | Meter technique or timing; missed glucose peaks; insufficient sensor data; altered red-cell turnover; assay interference | Compare dates and data quality, repeat the laboratory test, and use a glucose-based diagnostic test when indicated |
Home blood-glucose monitoring and continuous glucose monitoring can help reveal patterns, but current standards do not recommend CGM as a substitute for laboratory criteria when diagnosing prediabetes or diabetes.
A “false high” means the A1C is higher than the person’s actual average glucose would predict. The size and direction of the effect vary; the presence of a condition does not prove that the A1C is wrong.
Significant iron deficiency can raise A1C in some people, even without a corresponding rise in glucose. Treatment can lower A1C as iron status and red-cell production normalize. A1C should still be evaluated rather than dismissed, because iron deficiency and true dysglycemia can occur together. See the detailed guide to iron deficiency anemia blood tests and causes.
Deficiency that slows red-cell production may increase the average age of circulating red cells and can sometimes push A1C upward. The CBC pattern, nutrient results, symptoms, diet, medication history, and absorption risks matter. Learn more about vitamin B12 deficiency and autoimmune gastritis.
When red cells circulate longer, they have more time to accumulate glycated hemoglobin. Asplenia or prior splenectomy is one example that may alter interpretation. These situations are much less common than true dysglycemia, so evaluation should remain evidence-led.
Hemoglobin S, C, D, E, elevated fetal hemoglobin, and other variants can interfere with some A1C methods but not others. The direction of error may be high, low, or absent depending on the assay and the person’s hemoglobin pattern. Race or ethnicity should not be used as a proxy for a genetic variant. When a result is unexpected, the laboratory can identify the assay method, and the NGSP interference table can show whether that method is affected.
Severe hypertriglyceridemia or hyperbilirubinemia may interfere with particular methods. Modern assays have reduced many older interferences, so the laboratory method and current manufacturer information are more useful than a generic list.
Not every confounder causes a false high. Many shorten red-cell survival and tend to lower A1C; others make the direction unreliable.
| Clinical factor | Typical concern | Interpretation caution |
|---|---|---|
| Recent blood loss, hemolysis, or high red-cell turnover | Often falsely low | Younger circulating red cells have had less time for glycation. |
| Recent blood transfusion | Unpredictable | The result mixes the recipient’s and donor’s red-cell histories. |
| Erythropoietin therapy | Often falsely low | Increased production shifts the population toward younger red cells. |
| Advanced chronic kidney disease or dialysis | Often underestimates glycemia, but complex | Anemia, erythropoietin, transfusion, and shortened red-cell survival can outweigh older assay concerns. See Kidney Function Tests. |
| Pregnancy and the postpartum period | Relationship changes | Red-cell turnover and physiology change; A1C is not used to diagnose gestational diabetes. See Pregnancy Blood Tests and Prenatal Screening. |
| Liver disease, HIV treatment, or G6PD deficiency | May be low or otherwise discordant | The mechanism and direction depend on red-cell turnover, treatment, and disease severity. See Liver Function Tests. |
Some medicines raise A1C because they truly raise glucose. Examples include systemic corticosteroids and some antipsychotic, immunosuppressive, and other medicines. This is not a false result; it may represent medication-associated hyperglycemia that still deserves clinical attention.
Other medicines or treatments can alter A1C indirectly by causing hemolysis, blood loss, or a change in red-cell production. The direction of the mismatch depends on the mechanism. Bring a complete list of prescription medicines, over-the-counter products, supplements, recent injections or infusions, and start dates to the review. Do not stop or change a prescribed medicine because of an A1C result without guidance from the prescriber.
The goal is not to “prove the A1C wrong.” It is to find the explanation that best fits the laboratory pattern, symptoms, medical history, and timing.
Not everyone needs every test. The most useful set depends on whether the main question is diabetes confirmation, a red-cell problem, nutrient deficiency, a hemoglobin variant, or another health condition.
| Clinical question | Tests that may be considered | What the results add |
|---|---|---|
| Is the A1C reproducible, and how does it compare with fasting glucose? | Hemoglobin A1C and Glucose Panel | Places a longer-term marker and a same-draw glucose snapshot side by side. A fasting glucose requires the instructed fast; A1C itself does not. |
| Could anemia or abnormal red-cell indices be affecting A1C? | Complete Blood Count with Differential and Platelets | Reviews hemoglobin, hematocrit, MCV, RDW, and cell counts. A CBC suggests patterns but does not identify every cause by itself. |
| Could iron deficiency be present? | Ferritin and Iron and Total Iron-Binding Capacity | Ferritin estimates iron stores; iron, TIBC, and transferrin saturation add context. Inflammation can raise ferritin, so results should be read together. |
| Could a vitamin deficiency be slowing red-cell production? | Vitamin B12 and Folate, Serum | Supports evaluation for megaloblastic deficiency when symptoms, diet, medications, or CBC indices make it plausible. |
| Is red-cell production unusually high or low? | Reticulocyte Count | Shows the marrow’s red-cell production response and helps interpret anemia, blood loss, or recovery after treatment. |
| Could a hemoglobin variant be affecting the assay? | Hemoglobinopathy Evaluation | Assesses common hemoglobin patterns. The laboratory’s A1C method still matters because interference is method-specific. |
| Could kidney, liver, protein, or metabolic context affect interpretation? | Comprehensive Metabolic Panel | Provides glucose, kidney-related measures, liver enzymes, bilirubin, albumin, and electrolytes. It does not replace a dedicated kidney or liver evaluation. |
| Is a shorter-term glycemic marker needed because A1C is unreliable? | Fructosamine | Reflects glycated serum proteins over about two to three weeks. Albumin concentration and protein turnover can alter the result. |
| Could recent glucose excursions be relevant in an already diagnosed person? | 1,5-Anhydroglucitol (1,5-AG) | A supplemental, short-term marker influenced by renal glucose handling. It is not a diagnostic test for diabetes and can be misleading with SGLT2 inhibitors or kidney dysfunction. |
Thyroid disease can also change metabolic and red-cell context, but thyroid testing should be driven by symptoms and history rather than added automatically. For a focused overview, see Thyroid Blood Tests: TSH, Free T4, Free T3, and Thyroid Antibodies.
These tests reflect glycation of circulating proteins, primarily albumin, over approximately 15 to 30 days. They are not affected by red-cell lifespan, which can make them useful for monitoring when A1C is unreliable. However, low or rapidly changing albumin, significant protein loss, liver disease, nephrotic syndrome, and thyroid-related changes can complicate interpretation. Standardized diabetes diagnostic cutoffs are not established in the same way as for A1C and plasma glucose.
1,5-AG can fall when glucose exceeds the kidney’s reabsorption threshold, so it may reflect recent hyperglycemic excursions over roughly one to two weeks. Kidney function, pregnancy, renal glucose handling, and SGLT2 inhibitor therapy can substantially affect the result. It is an adjunct for selected monitoring questions—not a replacement for A1C, fasting plasma glucose, or OGTT in diagnosis. Read the dedicated comparison: 1,5-Anhydroglucitol (1,5-AG): When A1C May Miss Recent Glucose Spikes.
Biotin and other supplements can interfere with some laboratory assays, although A1C methods differ. Do not stop any supplement or medicine without checking the instructions and the clinician or laboratory.
Useful questions include:
Do not wait for a routine retest if you have symptoms of marked hyperglycemia or rapid deterioration. A result is only one part of the decision; symptoms and current glucose matter.
Seek urgent evaluation for vomiting with inability to keep fluids down, abdominal pain, fast or deep breathing, fruity-smelling breath, severe dehydration, confusion, fainting, or multiple symptoms of diabetic ketoacidosis. Marked thirst, frequent urination, unexplained weight loss, blurred vision, or severe weakness also warrant prompt clinical assessment—especially when a glucose result is very high. Diabetic ketoacidosis can be the first sign of previously undiagnosed diabetes.
Yes. An A1C of 5.7% to 6.4% is prediabetes, not diabetes. A diabetes-range A1C may be awaiting confirmation, and some red-cell or assay factors can make A1C discordant with true glucose exposure. “Not diagnosed yet” is different from “diabetes has been excluded.”
It can. Significant iron deficiency is associated with higher A1C in some people, and A1C may fall after iron treatment. The effect is not predictable enough to dismiss a high result, so glucose-based confirmation and an iron evaluation may both be appropriate.
Fasting glucose is one point in time. A1C integrates glucose exposure over weeks, including after-meal elevations. A normal fasting result can also coexist with a distorted A1C. Repeating the abnormal test and comparing an accepted glucose-based test helps distinguish these possibilities.
Short-term dehydration can affect a current glucose concentration, but it does not usually explain a sustained A1C by itself because A1C reflects glycation over weeks. Acute illness, current glucose, and sample context should still be reviewed.
A1C reflects roughly two to three months, but it is weighted toward recent weeks, so a meaningful change can begin to appear before three months. The right repeat interval depends on whether the goal is immediate diagnostic confirmation, monitoring treatment, or waiting for a red-cell condition to stabilize.
For diagnosis, use an accepted plasma-glucose criterion—such as fasting plasma glucose or a 75-gram two-hour OGTT—when the A1C–glucose relationship is altered. For monitoring, fructosamine or glycated albumin may help in selected cases, but their limitations and the person’s protein status must be considered.
No. Interference is method-specific, and many modern methods report accurate results for common heterozygous variants. The laboratory method, the specific variant, and whether red-cell survival is altered all matter.
Yes. Some medicines raise glucose and therefore raise A1C; others alter red-cell turnover and can create a mismatch. Review the mechanism and timing with the prescriber rather than stopping medication independently.
A high A1C without a diabetes diagnosis is a signal to clarify, not a contradiction to ignore. The result may reflect prediabetes, previously unrecognized diabetes, post-meal glucose elevations, altered red-cell turnover, or method-specific interference. Confirm diabetes-range results, compare the right plasma-glucose test, and investigate blood-count or assay factors when the pattern remains discordant.
Updated: August 27, 2026. Originally published October 3, 2023.
Editorial note: This article was substantively updated to reflect current diabetes diagnostic guidance, distinguish true dysglycemia from A1C interference, and correct the interpretation of red-cell turnover, kidney disease, hemoglobin variants, fructosamine, and 1,5-AG.
Disclosure: Ulta Lab Tests offers laboratory-testing services and may link to tests or panels discussed on this page. This content is educational and does not provide individual diagnosis or treatment.
Medical disclaimer: Laboratory results must be interpreted with symptoms, medical history, medications, and clinician guidance. This content is not a substitute for professional medical advice, diagnosis, or emergency care.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
